Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH stock opened at $0.02 on Tuesday. Bellerophon Therapeutics has a 52 week low of $0.02 and a 52 week high of $0.10. The firm has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.04. The stock has a market capitalization of $256,830.00, a P/E ratio of -0.03 and a beta of 0.74.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.